The Importance of Early Detection

Over 52,000 men are diagnosed with prostate cancer each year in the UK, and it remains the second leading cause of cancer-related death in men. However, most aggressive cancers are asymptomatic until later stages, making early risk assessment incredibly important. When detected early, prostate cancer boasts a 98–100% 10-year survival rate. This highlights the power of understanding your risk before symptoms even appear.

The Evolution of Screening: From PSA to PRS

PSA tests have been the gold standard for decades - but they come with caveats:

• False positives: Often leading to unnecessary biopsies (which can be uncomfortable and cause undue worry) and anxiety.
• Missed aggressive cancers: Especially in younger men.
• Elevated PSA levels: Can be caused by factors other than cancer.

This means that while PSA is a useful tool, it may not provide the precise information needed for true peace of mind.

From PSA to Polygenic Risk Score (PRS): The Testing Revolution

A groundbreaking study published in The New England Journal of Medicine (Eeles et al., 2024) has demonstrated that Polygenic Risk Scoring (PRS) significantly improves the accuracy of prostate cancer screening compared to PSA testing alone. PRS calculates an individual's inherited risk based on their unique genetic markers, offering a proactive approach to understanding your predisposition to the disease. The convenience of an at-home test makes it even more accessible.

Here’s what makes PRS testing different and why it's a game-changer:

• Genetic insights: PRS analyses numerous genetic variants to estimate your inherited risk.
• Early risk detection: It tells you how likely you are to develop the disease before symptoms begin, allowing for early intervention.
• More accurate: The NEJM study found that PRS identified more clinically significant cancers than PSA or MRI testing alone.
• Simple saliva test: Unlike blood tests, PRS testing can be done with a non-invasive saliva sample from the comfort of your home.

Vitall is proud to offer the UK's only at-home Prostate Cancer Risk Test using polygenic risk scoring. This test empowers you with the knowledge to take action early and plan for a healthier future.

What is BARCODE1?

BARCODE1 is a pioneering UK study assessing the feasibility and effectiveness of using a polygenic risk score (PRS) to guide prostate cancer screening in the general population. Here's a clearer breakdown:

Pilot & Main Study

• The BARCODE1 pilot (2021) enrolled ~300 men aged 55–69 via GP invitations. Participants sent saliva samples, which were genotyped for around 130 prostate cancer‑associated genetic variants to calculate individual PRS.

• Men in the top 10% of PRS were referred for further screening, including MRI and biopsy. Of those who underwent these tests, 39% were diagnosed with prostate cancer—though all cases were low-risk and managed with active surveillance.

Expanded Study

• The full BARCODE1 trial aimed to recruit ~5,000 men, continuing the strategy of PRS‑guided screening via saliva kits and follow-up imaging/biopsies for high‑risk individuals.

Latest Results

• New findings (NEJM, April 2025) show that among high‑PRS men, 40% were diagnosed with prostate cancer; over half (55%) were clinically significant.

• Notably, about 72% of these significant cancers would have been missed under standard PSA/MRI‑based pathways.

Why It Matters

1. Targeted Screening Works
   Using PRS to pre‑select high‑risk men improves detection rates of clinically significant cancers while potentially reducing unnecessary biopsies.

2. High Predictive Value
   The proportion of meaningful cancers detected in the selected group is substantially higher than would occur using PSA-based screening alone.

3. Expert Backing
   Independent commentary from experts like Prof Michael Inouye and UK clinicians supports PRS as a major step forward for early detection - though they stress the need for infrastructure, diversity in data, and long-term outcomes before NHS-wide implementation.

In Plain English

BARCODE1 proves that a simple, at-home saliva test using PRS is not only feasible, but it effectively identifies men at higher genetic risk. By funneling those men through further testing, the study uncovered more significant cancers that standard methods would have overlooked - all while sparing many men unnecessary procedures. It stands as a potential turning point toward precision-led prostate cancer screening in the UK.

Your Personalised Prevention Plan

So with that understanding or BARCODE1, we not only understand the need for early detection; but for providing next steps in how to actively mitigate risk. That's why our Prostate Cancer Risk Test doesn't just provide a score; it comes with a personalised prevention plan. This plan, tailored to your individual genetic profile, includes:

• Screening recommendations
• Lifestyle suggestions (nutrition, exercise, sleep, stress management)
• Guidance on the frequency of future screenings

This comprehensive approach helps you make informed choices about your health and actively reduce long-term risks.

Take Action This Prostate Cancer Prevention Action Week

• Men aged 40+, or those with a family history, should consider PRS testing this week.
• Share the message: “Knowing your risk is freedom—take control of your health.”
• Vitall’s PRS kit helps you get ahead, plan smarter, and steer proactively.

Knowing your risk isn't about fear; it's about freedom. The freedom to act, to plan, and to protect your future.

Your health is your most powerful weapon. Let's talk about it, and let's act early.